Company: INMB
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001213900-25-104141
Chunk: 1

Company: Inmune Bio, Inc.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
 27  
     22 
  
    Additional paid-in capital 
     229,888  
     195,754 
  
    Accumulated other comprehensive loss 
     (764) 
     (575)
  
    Accumulated deficit 
     (203,773) 
     (163,104)
  
    TOTAL STOCKHOLDERS’ EQUITY 
     25,378  
     32,097 

    TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY 
    $33,358  
    $39,562 

The accompanying notes are an integral part of
these unaudited condensed consolidated financial statements.

1

INMUNE BIO INC. 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS

(In thousands, except share and per share amounts)

(Unaudited)

    For the Three Months Ended September 30,  
    For the Nine Months Ended  September 30, 

    2025  
    2024  
    2025  
    2024 
  
    REVENUE 
    $-  
    $-  
    $50  
    $14 

    OPERATING EXPENSES 

    General and administrative 
     2,546  
     2,219  
     7,115  
     7,369 
  
    Research and development 
     4,887  
     10,067  
     18,330  
     25,813 
  
    Impairment of acquired in-process research and development intangible assets 
     -  
     -  
     16,514  
     - 
  
    Total operating expenses 
     7,433  
     12,286  
     41,959  
     33,182 

    LOSS FROM OPERATIONS 
     (7,433) 
     (12,286) 
     (41,909) 
     (33,168)

    OTHER INCOME, NET 
     961  
     193  
     1,240  
     304 

    NET LOSS 
    $(6,472) 
    $(12,093) 
    $(40,669) 
    $(32,864)

    Net loss per common share – basic and